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Summary: In this study we have analysed the influence of temperature and time of storage and of repeated
freezing on procalcitonin plasma concentrations ex vivo. We have also analysed the difference of procalcitonin
concentrations in arterial or venous blood samples and the influence of different anticoagulation techniques on
procalcitonin concentrations (serum, EDTA-, lithium-heparin- or citrate plasma). At room temperature (25 °C)
a loss of procalcitonin plasma concentrations of 6.4% ± 2.6% (mean, 2 standard error of the mean) after 3
hours (4.6% ± 5.2% at 4 °C) and 12.3% ± 3.1% after 24 hours occurred (6.3% ± 5.0% at 4°C, n = 17
each). Comparing the procalcitonin concentrations of blood samples with different anticoagulants (n = 24 each),
there was only a significant difference between procalcitonin concentrations in heparinized plasma and serum
(+ 7.6%, difference of the mean). There was no significant influence of the blood sampling technique (arterial
or venous line) and of repeated freezing/thawing cycles (up to 3 times) on the procalcitonin concentrations
measured. Although the difference of sampling and storage of the blood on procalcitonin concentrations is not
significant, multiple factors may act synergistically on the result of procalcitonin measurement. To keep
variations of ex vivo conditions as minimal as possible, a standardized technique of anticoagulation, time and
temperature of storage is recommended, e. g. the use of EDTA-plasma and storage at room temperature, when
samples are measured within 4 hours after blood drawing.
Introduction
The pathophysiology of procalcitonin 3. procalcitonin as prognostic marker and in the follow-
. . _ , . ., up of patients with severe infections, sepsis and multipleProcalcitonin is a protein consisting of 116 ammo acids , _ ,
. , . , , , „
 nnn. . . . . , organ dysfunction syndrome,(relative molecular mass about 13000) that is induced
in high concentrations in severe bacterial infections, sep- Except for immediate measurement in the acute disease,
sis and multiple organ dysfunction syndrome. Viral in- daily measurements are recommended for each patient,
fections, autoimmune disorders, allergic reactions, ma- A kit for the determination of procalcitonin (PCT) is
lignancies - apart from paraneoplastic production -, now commercially available (6). The "LUMItest®-PCT"
minor surgical procedures and local bacterial infections kit is an immunoluminometric assay. The reference limit
do not induce procalcitonin (1-5). of procalcitonin in healthy people is below 0.5 § 1,
at sepsis and at severe inflammation concentrations of
Three groups of indications for procalcitonin measure-
 more than 1000 § }-1 are reported ^  4) Bactenal £n_
ment can be summarized: dotoxins are a main stimulus for the induction of procal-
1. differential diagnosis of severe bacterial infections citonin (7, 8). Two to four hours after induction procalci-
from non-bacterial inflammation, e. g. viral versus bac- tonin concentrations rapidly rise and reach maximal
terial meningitis, toxic versus biliary induced pancreati- concentrations within 8 to 24 hours. Procalcitonin's half-
tis, bacterial versus non-bacterial etiology of acute respi- life time in vivo is about 24 hours. The origin of inflam-
ratory distress syndrome; matory induced procalcitonin is not known. Neuroendo-
crine cells of the lung, liver or the intestine are presently
2. infectious monitoring of severely ill patients, e. g. being discussed (2)
in multiple traumatized patients, after major surgical
procedures, at patients under immunosuppression;
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Aim of the study
Procalcitonin has recently been introduced into the rou-
tine diagnosis of severely ill patients. Daily measure-
ments are now established in numerous intensive care
units of major hospitals. As reference laboratory we are
often questioned about kind and time of storage of pro-
calcitonin, anticogulation and arterial or venous blood
sampling. According to general experience procalcitonin
is a very stable protein, also at room temperature. How-
ever, at present, no publications about the stability of
procalcitonin are available. Neither are data published
about the measurement of procalcitonin in different anti-
coagulants used for routine blood drawing or in serum
samples. According to the commercial provider of the
"LUMItest®-PCT"-kit, B.R.A.H.M.S.-Diagnostica, Ber-
lin, Germany, procalcitonin measurement should be
done within 4 hours after blood drawing (6). However,
patients with sepsis and acute infections may have an
increased proteolytic activity of their blood. This might
enhance degradation of procalcitonin, especially at high
concentrations of procalcitonin that indicates a maximal
stimulation of the cellular and humoral immunologic re-
sponse. On the other hand, blood samples from foreign
hospitals sometimes are kept at room temperature for
more than 4 hours by mailing before measurement. Thus
we have analysed the stability of procalcitonin in the
plasma of 17 patients of our intensive care unit with
different concentrations of procalcitonin at room tem-
perature and at 4 °C during a storage time of 0 to 24
hours. We have also frozen and thawed plasma samples
three times (—20 °C) to analyse changes caused by re-
peated freezing and thawing.
Further we have measured arterial and venous blood
samples drawn simultaneously, since blood is sometimes
drawn from either an arterial or a venous line.
The anticoagulation used may influence the measurement
of some analytes. Since procalcitonin is a new analyte, we
often get samples of either serum or plasma treated with
different anticoagulants from foreign hospitals. To inves-
tigate the influence of anticoagulants, we have measured
procalcitonin plasma concentrations in blood samples
drawn in syringes containing different commercially
available anticoagulants. Blood was drawn from procalci-
tonin-positive patients using simultaneously serum-mo-
novettes, lithium-heparinized, EDTA-, citrate-, and so-
dium fluoride-coated monovettes.
Materials and Methods
Procalcitonin was measured by the "LUMItest®-PCT"-kit
(B.R.A.H.M.S.-Diagnostica, Berlin, Germany) using the Auto-
CliniLumat LB 952 (Laboratorium Prof. Berthold, Wildbad, Ger-
many) according to the instructions of the manual (6): briefly, 20 μΐ
of samples (serum or plasma), standards and control serum are
incubated in the precoated test tube with 250 μΐ of tracer solution
each of the kit for 2 hours at room temperature on a horizontal rotator
(300 min ', darkness). The test tube is coated with a monoclonal an-
tibody specific for katacalcin. The tracer consists of an acridinium-
bound anti-calcitonin monoclonal antibody and a stabilisation buffer.
After incubation, the test tube is thoroughly rinsed three times using
the washing solution (LUMItest®-Washkit) and then dried upside
down for 10 minutes on a soft tissue. The dried test tubes are mea-
sured in the luminometer according to the test guidelines (e. g. 2
blanks, 6 standards, 2 controls, 2 patient samples each). For the mea-
surement NaOH (0.25 mol/1) and subsequent H2O2 (5 g/l tbOa in
0.1 mol/1 HNOs) is automatically injected into the tubes by the
double injector of the luminometer. The chemical reaction generates
a short emission of light and is measured as "relative light unit"
(RLU). Using the standards (concentration of 0.08,0.5,2.0,20,200,
500 μg 1~' procalcitonin) the actual concentration of the control- and
patient samples is calculated automatically by a spline algorithm
(3,4,6) and the results are printed immediately. The entire procedure
of measurement takes about 2 1/2 hours.
Stability of procalcitonin at room temperature (25 °C)
and 4 °C in plasma
Blood samples were drawn from 17 patients with increased procal-
citonin concentrations (diagnosis: sepsis, severe bacterial infection,
postoperatively increased procalcitonin concentrations) via an arte-
rial catheter. For anticoagulation a 10ml EDTA-monovette (Sar-
stedt Nr. 02.1063) was used. The blood was centrifuged (10 min,
600 g, 4 °C) within 5 minutes after drawing and the sample of time-
point 0 (control) was frozen immediately (—20 °C). The other
plasma was distributed into 1.5 ml closed cups of polypropylene
(Eppendorf, Germany) and was stored either at 25 °C or at 4 °C. At
different times (t = 1h, 3h, 6h, 24h) the respective sample was
also frozen (—20 °C). Then all samples were thawed and analyzed
simultaneously by the AutoCliniLumat LB 952 as described above.
Arterial and venous samples
Arterial and venous blood was drawn from 12 patients by means
of an EDTA-monovette (Sarstedt Nr. 03.1396) using both simulta-
neously, an arterial catheter and a central vena jugularis interna
catheter. Prior to asservation of the sample 5 ml blood were drawn
and discarded from the arterial line, and 10 ml from the venous
catheter. Blood was centrifuged at 600 g for 5 minutes (4 °C) and
plasma was stored at —20 °C for less than one week. Measurements
were performed using one "LUMItest®-PCT"-kit with simulta-
neous incubation for both arterial and venous samples.
Comparison of procalcitonin concentrations in serum
and plasma with different anticoagulants: lithium-
heparin, sodium fluoride, citrate and EDTA plasma
Blood was drawn from an arterial catheter in 24 patients, centri-
fuged and measured as described above. The following commer-
cially available syringes were used:
Serum:
— 10 ml monovette (containing clot-activating granulate, Sarstedt,
Germany, Nr. 02.1063)
Plasma:
— lithium-heparin plasma (lithium-heparin, 12—30 X 103 IU I"1,
Sarstedt Nr. 03.1628 and 05.1147.020), also used for blood gas
analysis (05.1147.020).
— sodium fluoride plasma (Sarstedt Nr. 05.1073.001), also used
for lactate measurement.
— citrate plasma (31.3 g/l tri-sodium-citrate-2-hydrate; dilution: 9
ml blood and 1 ml of citrate solution, Sarstedt Nr. 05.1071), nor-
mally used for measurement of coagulation constituents.
- EDTA plasma (potassium-EDTA, 1.2-2 g Γ', Sarstedt
Nr. 03.1396), used for peripheral blood counts and haematocrit
measurement.
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Repeated freezing and thawing
Blood samples (n = 8) were drawn with an EDTA-monovette (Sar-
stedt Nr. 03.1396) and centrifuged as described. The samples were
aliquotted into 1.5 ml polypropylene vials (Eppendorf). The con-
trols (no freezing) were analysed by the AutoCliniLumat LB 952
immediately. The other samples were frozen up to three times (55
minutes at —20 °C, 5 minutes in a water-bath at 25 °C until thaw-
ing) and were analysed immediately after each thawing as de-
scribed above.
Statistics
All samples were analysed as duplicate measurements calculating
the arithmetical average. The mean and standard error of the mean
(S. E. M.) were calculated for each group. For comparison of dif-
ferent treated samples of each patient the non-parametric Wilcoxon-
test for dependent samples was used for absolute procalcitonin con-
centrations (programme Statistica 4.5 for Windows). Statistical sig-
nificance was assumed with p < 0.05. To compare different treated
samples independently from the absolute concentration of procalci-
tonin, each value of one group (reference group, e. g. the serum
group) was defined as 100 percent and the respective values of the
different treated group were expressed as percent of variance of
the reference value. The mean and standard error of the mean (S. E.
M.) was calculated.
Results
Storage at 4 °C and 25 °C
The degradation of procalcitonin in plasma can be de-
scribed by a biphasic kinetic (fig. 1). After the first 3
hours after collection and storage at 25 °C 6.4% (mean)
of the original concentration are lost, that are about 2.1%
per hour. During the following 3 hours only 2.1% of
procalcitonin is degraded representing a decay of 0.7%
per hour. In the following 18 hours only 0.21% per hour
are lost (see fig. 1). This is a total degradation of 12.3%
within 24 hours. Within the first hour after collection
and storage at 4 °C of the sample concentrations were
increased in 82% of the samples with an increase of
12.4% in average. After 6 hours, 101.9% of the initial
concentration was measured (mean) and after a storage
of 24 hours at 4 °C, 93.7% of the original concentration
10 15
Time [h]
Fig. 1 Variations of procalcitonin plasma concentrations during
storage at 25 °C (·) and 4 °C (o) (EDTA plasma, n = 17 samples
each). Displayed are concentrations (mean) in percent of control
(t = 0, 100%) after storage of 1, 3, 6 and 24 hours. Error-bars
indicate standard error of the mean.
were found. The percentual decay was similar for high
(procalcitonin > 8 g I"1) and low (procalcitonin
< 8 g I"1) concentrations of procalcitonin both at
25 °C and 4 °C (tab. 1).
Repeated freezing and thawing
Repeated freezing and thawing did not significantly in-
flucence procalcitonin plasma concentrations (tab. 2).
The median of variance of three-times frozen samples
(n = 8) differed only 1.6% from that of non-frozen con-
trols (p = 0.6, Wilcoxon test).
Arterial and venous blood samples
Arterial procalcitonin concentrations did neither signifi-
cantly differ from venous plasma concentrations
(p = 0.239, Wilcoxon test for dependent samples,
n = 12), although procalcitonin concentrations were
4.1% higher (mean) in the arterial samples (tab. 3).
Serum and plasma with different
anticoagulants
Comparing the procalcitonin concentrations of blood
samples with different anticoagulants (n = 24 each),
Tab. 1 Effect of storage temperature on procalcitonin plasma
concentrations. Decrease of procalcitonin concentrations (mean,
EDTA plasma) in percent of control after storage at room temper-
ature (25 °C) and 4 °C for high and low plasma concentrations of
procalcitonin. Results are displayed as percent of controls (immedi-
ate measurement, t = 0) for plasma samples with high (> 8 g I"1
procalcitonin, mean 28.9 g I"1 procalcitonin, n = 8) and low (> 8
g I"1 procalcitonin, mean 4.8 g 1~! procalcitonin, n = 9)
plasma concentrations of procalcitonin. S. E. M., standard error of
the mean.
Storage
Temperature
25
25
25
25
4
4
4
4
Plasma procalcitonin recovery [% of control]
High concentrations (n = 8)
Duration
M
1
3
6
24
1
3
6
24
Mean
95.4
93.3
90.3
88.0
116.8
107.0
104.0
94.9
S.E.M.
2.6
2.8
1.9
2.9
4.6
3.2
3.0
3.5
Low concentrations (n = 9)
Mean
97.6
93.8
92.1
87.5
105.2
100.7
98.5
93.3
S.E.M.
1.1
1.4
1.6
1.9
5.6
4.2
3.0
3.4
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Tab. 2 Effect of freeze-thawing on procalcitonin plasma concen-
trations. Procalcitonin plasma concentrations (mean, EDTA
plasma) of frozen samples (n = 8, repeatedly frozen 1 to 3 times)
in percent of fresh plasma. S. E. M., standard error of the mean.
Freeze-
thawing
1 X
2 X
3 X
Plasma procalcitonin
recovery (n = 8)
[% of control]
101
98.9
101.6
S. E. M.
2.64
1.91
2.08
P
(Wilcoxon-
test)
0.249
0.600
0.600
Tab. 3 Influence of anticoagulants and sampling site on procalci-
tonin concentrations. Procalcitonin concentrations (mean) in
plasma containing different anticoagulants (n = 24 each) in percent
of serum concentrations. In addition, procalcitonin plasma concen-
trations in blood obtained from an arterial line (EDTA plasma)
are presented in percent of procalcitonin plasma concentrations,
measured in venous plasma. S. E. M., standard error of the mean.
Specimen
Serum
(Control, n = 24)
Citrate plasma
(n = 24)
EDTA plasma
(n = 24)
Lithium-heparin
plasma (n = 24)
Sodium fluoride
plasma (n = 24)
Venous EDTA
plasma
(control, n = 12)
Arterial EDTA
plasma (n = 12)
Procalcitonin S. E. M.
[% of control]
Mean
100
95.95 2.21
100.33 1.54
107.60 1.93
104.38 2.18
100
104.09 0.90
P
(Wilcoxon-
test)
0.145
0.932
0.004
0.052
0.239
there was only a significant difference between procalci-
tonin concentrations in heparinized plasma and serum.
Using serum concentrations as a reference, concentra-
tions of plasma procalcitonin differed + 7.6% for lith-
ium-heparinized plasma (p = 0.004, Wilcoxon test for
dependent samples), + 4.38% for sodium fluoride
plasma (p = 0.052), - 4.05% for citrate plasma (p =
0.145) and + 0.33% for EDTA-plasma (p = 0.932). As-
sessing procalcitonin concentrations of citrate plasma, a
9 + 1 dilution from the citrate solution of the monovette
should be considered. The comparison of the procalcito-
nin measurements in plasma samples with different anti-
coagulants or serum is shown in table 3.
Discussion
Procalcitonin ex vivo is a very stable protein even at
room temperature. Also repeated freezing and thawing
does not significantly influence procalcitonin plasma
concentrations. Arterial and venous samples do not dif-
fer in their concentrations of procalcitonin. Comparing
procalcitonin concentrations in plasma samples contain-
ing different types of anticoagulants with procalcitonin
in serum, a significant difference was only observed for
lithium-heparinized plasma. However, this difference is
very small and less than 8% in the mean. Likewise, the
loss of procalcitonin plasma concentrations due to stor-
age at 25 °C is low. Even after 24 hours of storage at
room temperature, only 12.4% (mean) of the original
concentration is lost, and 6.3% at 4 °C. The decay of
procalcitonin is maximal during the first hours (2.13%
per hour) after blood sampling and decreased after 6
hours (0.21% per hour). In some patients however, the
combined influence of different anticoagulants, the vari-
ance of the assay, differences of time and temperature
of storage might have synergistic effects and lead to a
mismeasurement of the actual plasma concentration.
Thus, we recommend a standardized procedure for as-
servation, anticoagulation and storage of procalcitonin
samples. Storage at room temperature is recommended,
when the time interval between blood drawing and mea-
surement of the samples is quite constant, e. g. in daily
routine diagnostic. Since the decay of procalcitonin in
plasma at room temperature follows a reproducible ki-
netic, the time interval from blood drawing to measure-
ment should be kept constant. This is important, since
maximum degradation occurs during the first hours after
drawing of the blood. For major intervals of storage, or
if constant intervals cannot be maintained, either freez-
ing or storage of the sample at 0—4 °C is recommended.
The increase of procalcitonin concentrations observed
during the first hours after blood drawing at 4 °C storage
cannot be explained sufficiently at present. From other
analytes, comparable observations are known and called
"fresh-plasma-effect". These effects are explained by ab-
sorption and release of the substance to plasma proteins.
Another explanation would be a decay of the whole pro-
tein of procalcitonin into smaller fragments, which also
have a very high affinity to the antibodies of the immu-
noluminometric assay. Based on the design of the assay,
also smaller molecules than the whole molecule of pro-
calcitonin react with the assay, e.g katacalcin-calcitonin
fragment sequences. The biphasic kinetic of degradation
might be also explained by a rapid decay of procalcito-
nin into smaller fragments, which is followed by a se-
cond or slow period of degradation of these fragments.
At present, there are no further data available to answer
this question.
In summary, procalcitonin, compared to other inflamma-
tion markers like cytokines, has the advantage of a great
stability at different conditions of storage (4, 5, 9). If a
precision of about ± 20% of the actual concentration is
considered sufficient, there is no need to follow special
guidelines for blood asservation. However, a decrease
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in procalcitonin concentrations occurs regularly due to
different time and temperature of storage and the use of
different anticoagulants. These factors may synergisti-
cally influence the procalcitonin measurement. Thus, a
standardized procedure for procalcitonin samples is re-
commended for clinical routine diagnosis and, espe-
cially, for the daily follow-up of patients. The use of one
specific anticoagulant or a certain temperature of storage
cannot be generally recommended but should be defined
in each hospital. In our institution, we decided to store
samples at room temperature, since the risk of temper-
ature inconsistancy is less than during refrigeration.
Blood drawing and measurement of procalcitonin is
done at the same time each day. We also use EDTA-
plasma, which is also recommended by the provider of
the "LUMItest®-PCT"-kit.
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